NCT00917306View on ClinicalTrials.gov

A Multi-center Study to Evaluate the Safety and Efficacy of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on Non-head Locations (Trunk and Extremities)

PHASE3CompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

September 30, 2009

Study Completion Date

September 30, 2009

Conditions
Actinic Keratosis
Interventions
DRUG

PEP005 Gel

0.05% two day treatment

Trial Locations (11)

3141

Dermatology Institute of Victoria, Melbourne

5006

Dematology on Ward, Adelaide

6008

St John of God Dermatology, Subiaco

14623

Dermatology Associates of Rochester, Rochester

30263

Medaphase Inc, Newnan

32073

Park Avenue Dermatology, Orange Park

37203

Dermatology Research Associates, Nashville

48038

Michigan Center for Research Corp, Clinton Twp

48202

Henry Ford Health Systems, Detroit

30078-3250

Gwinnett Clinical Research Centre, Snellville

97239-4501

Oregon Health and Science University, Portland

Sponsors

Lead Sponsor

Peplin
All Listed Sponsors
collaborator

TKL Research, Inc.

INDUSTRY

lead

Peplin

INDUSTRY

NCT00917306 - A Multi-center Study to Evaluate the Safety and Efficacy of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on Non-head Locations (Trunk and Extremities) | Biotech Hunter | Biotech Hunter